TMAM
NBIX icon

Tokio Marine Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Tokio Marine Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$938K Buy
5,568
+90
+2% +$13.4K 0.03% 405
2026
Q1 		$722K Buy
5,478
+510
+10% +$67.7K 0.03% 430
2025
Q4 		$705K Buy
4,968
+171
+4% +$24.8K 0.02% 434
2025
Q3 		$673K Hold
4,797
– – 0.02% 438
2025
Q2 		$603K Buy
4,797
+188
+4% +$21.6K 0.02% 447
2025
Q1 		$510K Buy
4,609
+426
+10% +$54K 0.02% 474
2024
Q4 		$571K Sell
4,183
-119
-3% -$14.7K 0.02% 447
2024
Q3 		$496K Buy
4,302
+113
+3% +$15.5K 0.02% 464
2024
Q2 		$577K Buy
4,189
+434
+12% +$59.5K 0.03% 394
2024
Q1 		$518K Buy
3,755
+707
+23% +$96.6K 0.03% 427
2023
Q4 		$402K Buy
3,048
+107
+4% +$12.3K 0.02% 463
2023
Q3 		$331K Buy
2,941
+344
+13% +$36.2K 0.02% 473
2023
Q2 		$245K Buy
2,597
+86
+3% +$8.4K 0.02% 527
2023
Q1 		$254K Sell
2,511
-893
-26% -$92.9K 0.02% 503
2022
Q4 		$407K Buy
3,404
+1,297
+62% +$152K 0.03% 358
2022
Q3 		$224K Buy
+2,107
New +$214K 0.02% 457

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tokio Marine Asset Management's NBIX Position: Q2 2026 in Review

Tokio Marine Asset Management increased its Neurocrine Biosciences (NBIX) stake by 1.6% in Q2 2026, buying an estimated $13.4K and bringing the position to 5,568 shares worth $938K. The position accounts for 0.03% of the portfolio, ranked #405.

Tokio Marine Asset Management first reported a position in NBIX in Q3 2022 and has held it in 16 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Tokio Marine Asset Management held 5,568 shares of Neurocrine Biosciences worth $938K as of Q2 2026.
  • Tokio Marine Asset Management bought 90 Neurocrine Biosciences shares in Q2 2026, an estimated $13.4K.
  • Neurocrine Biosciences made up 0.03% of Tokio Marine Asset Management's portfolio in Q2 2026, its #405 holding.
  • Tokio Marine Asset Management first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 16 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Tokio Marine Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.